Described herein is an oral care implement comprising: a handle; and a head coupled to the handle, the head comprising a main body and a release component coupled to the main body, the release component comprising: a water-dissolvable matrix comprising a first polymer having a processing temperature greater than or equal to 130° C.; and a release agent comprising at least one of zinc oxide, potassium nitrate, and tetrapotassium pyrophosphate; wherein the release agent is dispersed throughout the water-dissolvable matrix.

Provided are a biodegradable sheet with antiviral properties, a manufacturing method thereof, and the use thereof. The biodegradable sheet comprises: a biodegradable polymer resin consisting of a polylactic acid-based polymer; or a composite degradable polymer resin comprising of a biodegradable resin and a petrochemical resin; and particles of an inorganic antiviral agent or aggregated composite particles of at least two inorganic antiviral agents incorporated into the biodegradable sheet so that the inorganic antiviral agent can be dispersed with a particle size of 100 to 900 nm.

Systems and methods are provided for fabricating microneedle arrays that includes electrospun fibers preferentially disposed within the microneedles of the array. Providing the electrospun fibers preferentially in the microneedles allows for more of a drug or other substance present in the fibers to be deposited into tissue or to provide other benefits. A mold for forming the microneedle arrays includes an insulating surface layer. The insulating surface layer affects the electric field during electrospinning such that electrospun fibers are deposited preferentially within the microneedle cavities of the mold relative to the surface of the mold. A bulk material can then be applied to the mold to form the bulk of the microneedles with electrospun fibers embedded within and a backing layer to which the microneedles are attached.

In the preferred embodiment, a method of making microneedles comprises i) providing a microneedle template (300) having a plurality of microneedles cavities (360) on one surface, ii) preparing a casting solution (320) comprising at least one matrix material and its solvent, iii) subjecting said microneedle template (300) to a vacuum pressure for a length of time to deprive it of air, iv) dispensing the casting solution (320) over the air-deprived microneedle template, v) allowing the casting solution (320) to be drawn into the air-deprived microneedle cavities (360) completely, and vi) allowing the dissolving microneedles to solidify or dry in a controlled environment.

The invention is to provide a hydrogen sulfide sustained releasing dressing and a manufacturing method thereof. The hydrogen sulfide sustained releasing dressing includes a hydrocolloid, a surfactant and sodium hydro sulfide. The manufacturing method includes (a) heating and stirring a hydrocolloid material; (b) adding a surfactant and sodium hydrosulfide into the hydrocolloid material; and (c) injecting the hydrocolloid material containing the surfactant and the sodium hydrosulfide into a mold for thermoforming a hydrogen sulfide sustained releasing dressing.

The present invention discloses solid oromucosal pharmaceutical formulations containing a psychedelic selected from psilocybin, psilocin, or mescaline and/or an analog thereof as an active ingredient, a method of preparation of the pharmaceutical form by Selective Laser Sintering (SLS) 3D printing, and treatment of neurological and/or psychiatric disorders, as well as inflammatory disorders.

Provided herein are devices and systems for depositing a material or manufacturing a product, such as a pharmaceutical dosage form, by additive manufacturing. Further provided are methods of using the devices and systems, as well as methods of manufacturing a product, such as a pharmaceutical dosage form, by additive manufacturing. In certain embodiments, the device includes a material supply system configured to melt an pressurized a material, a pressure sensor configured to detect a pressure of the material within the device, and a control switch comprising a sealing needle operable in an open position and closed position. The sealing needle extends through a feed channel containing the material and includes a taper end, wherein the tapered end of the sealing needle engages a tapered inner surface of a nozzle to inhibit flow of the material through the nozzle when the sealing needle is in the closed position.

The invention provides a solid-dosage-form printing apparatus comprising: i) a 3D printer suitable for printing solid-dosage-forms, said 3D printer comprising an interchangeable print head selected from the group consisting of: a fused deposition modelling print head, a semi-solid extrusion print head and a direct powder extrusion print head; ii) a build platform; iii) a balance for measuring the mass of the printed solid-dosage-forms, said balance being integrated into said build platform; and optionally iv) means for performing in-line near-infra-red and/or raman spectroscopy on the solid-dosage-form product; wherein said solid-dosage-form comprises at least one active-ingredient and at least one excipient. Further provided are methods of producing solid-dosage-forms using the apparatus, including computer-implemented methods.

Transdermal medicaments containing cannabidiol (CBD) for use in the amelioration of conditions, including anxiety, depression, pain, inflammation, epilepsy, parkinson's disease, oxidative injury and nausea; and a method for preparing same.

The present invention pertains to novel bone graft substitute materials. These materials are porous, homogenously dispersed solid mixtures of calcium phosphate and pro-regenerative extracellular matrix (ECM)—and potentially any pharmaceutical agent and/or mineral—that have been infused with polydopamine. In some embodiments the bone graft materials have osteoinductive factors incorporated within them.